FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285083321> ?p ?o ?g. }

• W4285083321 endingPage "711" @default.
• W4285083321 startingPage "703" @default.
• W4285083321 abstract "Abstract Objectives To investigate the therapeutic effect of Bicalutamide, an androgen receptor antagonist on the onset and development of allergic rhinitis in an animal model. Methods 40 male BALB/c mice were randomly divided into five groups (eight mice per group). Aluminum hydroxide powder was used as an adjuvant, combined with Ovalbumin (OVA) to establish the mouse model of allergic rhinitis via ultrasonic nebulization of OVA to stimulate the nasal cavity. Mice in Bica#1 group were intraperitoneally injected with 0.02 mg Bicalutamide/0.5 ml of normal saline daily for 7 consecutive days; mice in Bica#2 group were administered 0.02 mg Bicalutamide/0.5 ml of normal saline via intraperitoneal injection for 5 consecutive days, and then the same amount of normal saline was injected intraperitoneally for 2 consecutive days. Enzyme-linked immunosorbent assay was adopted to detect the serological levels of IgE, IL-4, and IL-6 production. Eosinophil infiltration was observed under microscope after hematoxylin and eosin staining of nasal mucosa. Quantitative PCR and Western blot were employed for determination of histamine receptors mRNA expression and PI3K/PKB associated protein levels, respectively. Results Histological analysis shown that allergic lesion was induced after OVA sensitization. Intraperitoneal injection with 0.02 mg Bicalutamide daily for 7 consecutive days significantly reduced the allergic lesion; however, mice injected with the same amount of normal saline at the same time demonstrated no allergic rhinitis symptoms. In addition, there was a significant reduction in eosinophils number in Bicalutamide treated mice ( n = 8) compared to the OVA group ( n = 8) (OVA: 19.6 ± 5.3 vs. Bica#1: 7.7 ± 0.8 vs. Bica#2: 9.4 ± 1.2, both p < 0.01). Furthermore, ELISA results revealed that the serological levels of IgE (OVA: 17.3 ± 1.7 µg/ml vs. Bica#1: 9.2 ± 0.6 vs. Bica#2: 10.4 ± 2.3, both p < 0.05), IL-4 (OVA: 164.3 ± 5.1 pg/ml vs. Bica#1: 110.2 ± 3.1 vs. Bica#2: 115.3 ± 4.1, both p < 0.05) and IL-6 (OVA: 167.3 ± 3.7 pg/ml vs. Bica#1: 117.5 ± 6.5 vs. Bica#2: 114.8 ± 2.4, both p < 0.05) were significantly decreased after two different dosage of Bicalutamide treatment. Similarly, histamine receptors in mast cells were significantly reduced after two different dosage of Bicalutamide treatment. More importantly, p-PKB protein was notably reduced after two different dosage of Bicalutamide treatment compared to the OVA group, mTOR protein levels were also down regulated after two different dosage of Bicalutamide treatment. Conclusions Our data demonstrated that androgen receptor antagonist Bicalutamide can significantly alleviate allergic rhinitis lesion in the animal model. PI3K/PKB activity in mast cells was suppressed after Bicalutamide injection. Our results provide important implication in allergic rhinitis prevention and treatment." @default.
• W4285083321 created "2022-07-14" @default.
• W4285083321 creator A5029203032 @default.
• W4285083321 creator A5069290234 @default.
• W4285083321 creator A5071773009 @default.
• W4285083321 creator A5080856341 @default.
• W4285083321 creator A5085727632 @default.
• W4285083321 creator A5090585862 @default.
• W4285083321 date "2022-07-13" @default.
• W4285083321 modified "2023-10-09" @default.
• W4285083321 title "Bicalutamide, an androgen receptor antagonist, effectively alleviate allergic rhinitis via suppression of PI3K–PKB activity" @default.
• W4285083321 cites W1907855477 @default.
• W4285083321 cites W1964841658 @default.
• W4285083321 cites W1974245465 @default.
• W4285083321 cites W1976071270 @default.
• W4285083321 cites W2002361100 @default.
• W4285083321 cites W2073100248 @default.
• W4285083321 cites W2128316560 @default.
• W4285083321 cites W2142578494 @default.
• W4285083321 cites W2214696316 @default.
• W4285083321 cites W2282197705 @default.
• W4285083321 cites W2282773014 @default.
• W4285083321 cites W2597432644 @default.
• W4285083321 cites W2605513847 @default.
• W4285083321 cites W2730832359 @default.
• W4285083321 cites W2767651709 @default.
• W4285083321 cites W2809132731 @default.
• W4285083321 cites W2887277853 @default.
• W4285083321 cites W2887592114 @default.
• W4285083321 cites W2920821891 @default.
• W4285083321 cites W3020076945 @default.
• W4285083321 doi "https://doi.org/10.1007/s00405-022-07538-w" @default.
• W4285083321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35831673" @default.
• W4285083321 hasPublicationYear "2022" @default.
• W4285083321 type Work @default.
• W4285083321 citedByCount "1" @default.
• W4285083321 countsByYear W42850833212023 @default.
• W4285083321 crossrefType "journal-article" @default.
• W4285083321 hasAuthorship W4285083321A5029203032 @default.
• W4285083321 hasAuthorship W4285083321A5069290234 @default.
• W4285083321 hasAuthorship W4285083321A5071773009 @default.
• W4285083321 hasAuthorship W4285083321A5080856341 @default.
• W4285083321 hasAuthorship W4285083321A5085727632 @default.
• W4285083321 hasAuthorship W4285083321A5090585862 @default.
• W4285083321 hasBestOaLocation W42850833211 @default.
• W4285083321 hasConcept C104317684 @default.
• W4285083321 hasConcept C121608353 @default.
• W4285083321 hasConcept C125473707 @default.
• W4285083321 hasConcept C126322002 @default.
• W4285083321 hasConcept C134018914 @default.
• W4285083321 hasConcept C170493617 @default.
• W4285083321 hasConcept C185592680 @default.
• W4285083321 hasConcept C203014093 @default.
• W4285083321 hasConcept C204232928 @default.
• W4285083321 hasConcept C2776042228 @default.
• W4285083321 hasConcept C2776415932 @default.
• W4285083321 hasConcept C2776885963 @default.
• W4285083321 hasConcept C2776946954 @default.
• W4285083321 hasConcept C2777037409 @default.
• W4285083321 hasConcept C2777397205 @default.
• W4285083321 hasConcept C2780159080 @default.
• W4285083321 hasConcept C2780192828 @default.
• W4285083321 hasConcept C2780962315 @default.
• W4285083321 hasConcept C55493867 @default.
• W4285083321 hasConcept C61367390 @default.
• W4285083321 hasConcept C71924100 @default.
• W4285083321 hasConcept C8891405 @default.
• W4285083321 hasConcept C98274493 @default.
• W4285083321 hasConceptScore W4285083321C104317684 @default.
• W4285083321 hasConceptScore W4285083321C121608353 @default.
• W4285083321 hasConceptScore W4285083321C125473707 @default.
• W4285083321 hasConceptScore W4285083321C126322002 @default.
• W4285083321 hasConceptScore W4285083321C134018914 @default.
• W4285083321 hasConceptScore W4285083321C170493617 @default.
• W4285083321 hasConceptScore W4285083321C185592680 @default.
• W4285083321 hasConceptScore W4285083321C203014093 @default.
• W4285083321 hasConceptScore W4285083321C204232928 @default.
• W4285083321 hasConceptScore W4285083321C2776042228 @default.
• W4285083321 hasConceptScore W4285083321C2776415932 @default.
• W4285083321 hasConceptScore W4285083321C2776885963 @default.
• W4285083321 hasConceptScore W4285083321C2776946954 @default.
• W4285083321 hasConceptScore W4285083321C2777037409 @default.
• W4285083321 hasConceptScore W4285083321C2777397205 @default.
• W4285083321 hasConceptScore W4285083321C2780159080 @default.
• W4285083321 hasConceptScore W4285083321C2780192828 @default.
• W4285083321 hasConceptScore W4285083321C2780962315 @default.
• W4285083321 hasConceptScore W4285083321C55493867 @default.
• W4285083321 hasConceptScore W4285083321C61367390 @default.
• W4285083321 hasConceptScore W4285083321C71924100 @default.
• W4285083321 hasConceptScore W4285083321C8891405 @default.
• W4285083321 hasConceptScore W4285083321C98274493 @default.
• W4285083321 hasIssue "2" @default.
• W4285083321 hasLocation W42850833211 @default.
• W4285083321 hasLocation W42850833212 @default.
• W4285083321 hasLocation W42850833213 @default.
• W4285083321 hasOpenAccess W4285083321 @default.
• W4285083321 hasPrimaryLocation W42850833211 @default.
• W4285083321 hasRelatedWork W2004261902 @default.

• next